Crossmark Global Holdings Inc. Acquires 1,709 Shares of Illumina, Inc. (NASDAQ:ILMN)

Crossmark Global Holdings Inc. grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 19.0% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 10,693 shares of the life sciences company’s stock after acquiring an additional 1,709 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Illumina were worth $1,395,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in ILMN. Janney Montgomery Scott LLC lifted its holdings in shares of Illumina by 41.5% in the 1st quarter. Janney Montgomery Scott LLC now owns 3,070 shares of the life sciences company’s stock worth $422,000 after acquiring an additional 900 shares during the last quarter. Empowered Funds LLC raised its position in Illumina by 26.9% in the 1st quarter. Empowered Funds LLC now owns 3,340 shares of the life sciences company’s stock worth $459,000 after purchasing an additional 708 shares during the period. Concurrent Investment Advisors LLC purchased a new stake in Illumina in the 1st quarter worth about $307,000. Sei Investments Co. lifted its stake in Illumina by 309.3% in the first quarter. Sei Investments Co. now owns 71,143 shares of the life sciences company’s stock worth $9,769,000 after purchasing an additional 53,761 shares during the last quarter. Finally, QRG Capital Management Inc. boosted its position in shares of Illumina by 25.4% during the first quarter. QRG Capital Management Inc. now owns 6,874 shares of the life sciences company’s stock valued at $944,000 after buying an additional 1,393 shares during the period. Institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. StockNews.com started coverage on Illumina in a research note on Thursday, August 29th. They set a “buy” rating for the company. Robert W. Baird lifted their target price on Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. TD Cowen upped their price target on shares of Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Scotiabank reduced their price target on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a research note on Thursday, August 15th. Finally, Stephens boosted their price objective on shares of Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and a consensus price target of $164.00.

Illumina Stock Performance

Shares of ILMN opened at $146.17 on Thursday. Illumina, Inc. has a 12 month low of $92.69 and a 12 month high of $156.66. The stock has a fifty day moving average price of $138.84 and a 200-day moving average price of $123.95. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. The firm has a market cap of $23.18 billion, a PE ratio of -14.68 and a beta of 1.13.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same period last year, the firm posted $0.33 EPS. Illumina’s revenue was down 3.5% on a year-over-year basis. Equities research analysts predict that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.